Weekly national Influenza and COVID-19 surveillance report
Week 41 report (up to week 40 data)
14 October 2021
Contents

Executive summary ........................................................................................................................................... 4
Laboratory surveillance ..................................................................................................................................... 6
  Confirmed COVID-19 cases (England) ........................................................................................................... 6
  Possible SARS-CoV-2 reinfection in England ................................................................................................. 18
  Respiratory DataMart system (England) ......................................................................................................... 21
Community surveillance ...................................................................................................................................... 24
  Acute respiratory infection incidents .................................................................................................................. 24
  COVID-19 cases by type of residence .................................................................................................................. 32
  FluSurvey .......................................................................................................................................................... 33
  FluDetector ...................................................................................................................................................... 35
  Google search queries ........................................................................................................................................ 37
  NHS 111 .......................................................................................................................................................... 39
Primary care surveillance .................................................................................................................................... 42
  RCGP (England) ................................................................................................................................................. 42
  UK .................................................................................................................................................................... 44
  GP In Hours, Syndromic Surveillance .................................................................................................................. 45
  GP Out of Hours, Syndromic Surveillance .......................................................................................................... 47
  Sentinel swabbing scheme in the UK .................................................................................................................... 49
Secondary care surveillance ............................................................................................................................... 51
  SARI Watch ...................................................................................................................................................... 51
  Hospitalisations, SARI Watch .............................................................................................................................. 52
  ICU or HDU admissions, SARI Watch .................................................................................................................. 56
  ECMO, SARI Watch ......................................................................................................................................... 60
  RSV admissions, SARI Watch ............................................................................................................................ 61
  Emergency Department attendances, Syndromic surveillance ........................................................................... 63
Mortality surveillance ............................................................................................................................................. 67
  Cumulative COVID-19 deaths ............................................................................................................................ 67
  Daily excess all-cause mortality (England) ........................................................................................................ 72
Microbiological surveillance ............................................................................................................................... 76
Virus characterisation .............................................................................................................................. 76
Antiviral susceptibility .............................................................................................................................. 77
SARS-CoV-2 variants ............................................................................................................................... 77
Antimicrobial susceptibility .................................................................................................................... 78
COVID-19 sero-prevalence surveillance ................................................................................................. 79
Seroprevalence in Adults aged 17 years and older (Blood Donors) ......................................................... 79
Influenza vaccination ............................................................................................................................... 84
Influenza vaccine uptake in GP patients .................................................................................................. 84
COVID-19 vaccination ............................................................................................................................. 85
COVID-19 vaccine uptake in England ...................................................................................................... 85
International update ............................................................................................................................... 89
Global COVID-19 update ......................................................................................................................... 89
Global influenza update ............................................................................................................................ 91
Other respiratory viruses ......................................................................................................................... 93
Related links ............................................................................................................................................... 94
About the UK Health Security Agency ................................................................................................... 95
Executive summary

From Friday 1 October 2021, the UK Health Security Agency (UKHSA) became fully operational. UKHSA takes on the health protection responsibilities of Public Health England (PHE) and incorporates NHS Test & Trace and the Joint Biosecurity Centre (JBC). UKHSA is an executive agency of the Department of Health and Social Care. It is responsible for planning, preventing and responding to public health threats, and providing intellectual, scientific and operational leadership at national and local level, as well as on the global stage.

This report summarises the information from the surveillance systems which are used to monitor coronavirus (COVID-19), influenza, and other seasonal respiratory viruses in England. References to COVID-19 represent the disease name and SARS-CoV-2 represent the virus name. The report is based on data from week 40 (between 4 October and 10 October 2021) and for some indicators daily data up to 12 October 2021.

Surveillance indicators suggest that at a national level COVID-19 activity increased in some indicators, while remaining stable in others in week 40 of 2021. Laboratory indicators suggest that influenza activity is very low.

Overall COVID-19 case rates increased in week 40. Case rates increased in all age groups and regions and remained stable or increased in most ethnic groups. Overall Pillar 1 remained stable and Pillar 2 positivity increased slightly compared to the previous week.

The overall number of reported acute respiratory incidents in the past week increased compared to the previous week. SARS-CoV-2 was identified in the majority of these.

COVID-19 hospitalisations increased slightly in week 40. Deaths with COVID-19 decreased slightly in the most recent week.

COVID-19 vaccine coverage was 65.5% for dose 1 at the end of week 40. COVID-19 vaccine coverage was 60.4% for dose 2 at the end of week 40, reaching over 90% in all cohorts over the age of 65 years and over 80% in all cohorts over 50 years. Seroprevalence data indicates that approximately 98.1% of blood donors aged 17 and over have antibodies to SARS-CoV-2 from either infection or vaccination.

Through Respiratory Datamart, there were 15 influenza positive samples detected in week 40. Other indicators for influenza such as hospital admissions and GP influenza-like illness consultation rates remain very low. Respiratory syncytial virus positivity increased slightly to 8.5% in week 40, while rhinovirus positivity decreased to 14.8% in week 40. Parainfluenza, adenovirus and human metapneumovirus (hMPV) positivity remained low at 2.0%, 1.6% and 2.9% respectively in week 40.
In this week’s report, influenza vaccine uptake is included for the first time for the 2021 to 2022 season.
Laboratory surveillance

Confirmed COVID-19 cases (England)

As of 9am on 12 October 2021, a total of 7,000,356 first positive cases have been confirmed for COVID-19 in England under Pillars 1 and 2, since the beginning of the pandemic.

Overall COVID-19 case rates increased in week 40. Case rates increased in all age groups and regions and remained stable or increased in most ethnic groups. Overall Pillar 1 remained stable and Pillar 2 positivity increased slightly compared to the previous week.

From the week 32 report onwards, case rates have been updated to use the latest ONS population estimates for mid-2020. Previously case rates were calculated using the mid-2019 population estimates. Rates by ethnicity and IMD quantile will continue to be presented using the mid-2019 estimates, until the mid-2020 estimates become available.

Please note that positivity is presented as positivity by Polymerase Chain Reaction (PCR) testing only, unless otherwise stated (for example figure 2).

Changes to testing policies over time may impact on positivity rates.

Figure 1: Confirmed COVID-19 cases tested under Pillar 1 and Pillar 2, based on sample week with overall weekly PCR positivity for Pillars 1 and 2 (%)

* The data are shown by the week the specimen was taken from the person being tested. This gives the most accurate analysis of this time progression, however, for the most recent week results for more samples are expected therefore this should be interpreted with caution.

* Positivity (excluding Figure 2) is calculated as the number of individuals testing positive during the
week divided by the number of individuals tested during the week through Polymerase Chain Reaction (PCR) testing
* Data source: Second Generation Surveillance System (SGSS)

**Figure 2: Weekly positivity (%) of confirmed COVID-19 and number of individuals tested by type of test, under Pillar 1 and 2**

* For Figure 2 positivity is calculated as the number of individuals testing positive using a specific test type during the week, divided by the number of individuals tested using that specific test type during the week
* Please note that an individual may appear under both PCR and LFD tests if they have been tested using both test types in a given week
Age and sex

Figure 3: Age-sex pyramids for confirmed COVID-19 cases tested under Pillars 1 and 2 in weeks 39 and 40 (n=400,972)
Figure 4: Weekly confirmed COVID-19 case rates per 100,000, tested under Pillar 1 and Pillar 2, by sex

Figure 5: Weekly confirmed COVID-19 case rates per 100,000, tested under Pillar 1 and Pillar 2, by age group
Figure 6: Weekly PCR positivity (%) of confirmed COVID-19 cases tested overall and by sex under (a) Pillar 1 and (b) Pillar 2
Figure 7: Weekly PCR positivity (%) of confirmed COVID-19 cases tested under Pillar 1, (a) by male and age group and (b) by female and age group and; under Pillar 2, (c) by male and age group and (d) by female and age group

(a) Pillar 1 - Male

(b) Pillar 1 - Female
Weekly National Influenza and COVID-19 Report: week 41 report (up to week 40 data)

(c) Pillar 2 – Male

(d) Pillar 2 – Female
Geography

Figure 8: Weekly confirmed COVID-19 case rates per 100,000 population (Pillar 1 and Pillar 2), by UKHSA Centres and sample week
Figure 9: Weekly PCR positivity of confirmed COVID-19 cases tested under (a) Pillar 1 (%) and (b) Pillar 2 (%), by UKHSA Centres and sample week.
Figure 10: Weekly rate of COVID-19 cases per 100,000 population (Pillar 1 and 2), by upper-tier local authority, England (box shows enlarged map of London area)
Ethnicity

**Figure 11: Weekly incidence per 100,000 population by ethnicity, England**

*the incidence rates on Figure 11 have been calculated using the mid-2019 ONS population estimates*
Positivity by symptoms

Figure 12: Weekly PCR positivity (%) of confirmed COVID-19 cases by symptoms reported on Pillar 2 test request
Possible SARS-CoV-2 reinfection in England

Please note that this section will be updated monthly. Last update was published 16 September 2021.

The following figures present population data based on the first time that individuals tested positive for SARS-CoV-2 through PCR and/or lateral flow device testing in England together with those who have tested positive for SARS-CoV-2 through PCR and/or lateral flow testing with an interval of at least 90 days between two consecutive positive tests. To the end of week 34 in 2021 (to 29 August 2021) 45,119 possible reinfections have been identified, of which 259 have been confirmed by identification of genetically distinct specimens from each illness episode to end August 2021 (see Table 1).

For a possible reinfection to be categorised as confirmed it requires sequencing of a specimen at each episode and for the later specimen to be genetically distinct from that sequenced from the earlier episode. Availability of such dual sequencing is currently very low for several reasons; sequencing was not widely undertaken early in the pandemic; LFD test results do not allow sequencing and some PCR samples have a low viral load where sequencing cannot be undertaken. To meet the definition of a probable reinfection requires sequencing at the later episode that identifies a variant that was not circulating at the time of the earlier episode. Further details on the methodology, as well as additional data on reinfections are available in the graph set published alongside this report.

It is important to consider reinfections in the context of first infections and there is a 90-day delay before people with a first infection can become eligible for reinfection.

Table 1 summarises the definitions of different categories of COVID-19 infection accompanied by totals generated to 29 August 2021 (end week 34 2021) and review of 5,014 possible reinfections with sequencing data available to end August 2021. These data are skewed by the limited availability of sequencing data, particularly in the early months of the pandemic. More recently, widespread routine testing of asymptomatic individuals has taken place and this, together with surge testing, will lead to an increased number of asymptomatic reinfections being identified.

Figure 13 shows the weekly rates of possible reinfections per 1000 first infections based on a cumulative denominator derived from total individuals with a first SARS-CoV-2 positive test result at a point 13 weeks (91 days) before the second positive test result together with the cumulative total of first infections (secondary Y-axis) and total first infections (secondary Y-axis) by week of onset.
**Table 1: Different categories of COVID-19 infection with current totals generated by ongoing analysis in England to 29 August 2021 (end week 34 2021)**

<table>
<thead>
<tr>
<th>Infection type</th>
<th>Definition</th>
<th>Current totals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary infection/first positive</td>
<td>the first positive PCR/ LFD test result for an individual</td>
<td>5.9 million first positives</td>
</tr>
<tr>
<td>Possible reinfection</td>
<td>identified based on two sequential positive test results (PCR or LFD) at least 90 days apart</td>
<td>45,119 possible reinfections</td>
</tr>
<tr>
<td>Probable reinfection</td>
<td>where only reinfection sample is available, and this is congruent with contemporaneous phylogeny OR the second event identifies a variant which was not in circulation at the time of first infection</td>
<td>2,981 classified as probable*</td>
</tr>
<tr>
<td>Confirmed reinfection</td>
<td>sequencing of a specimen at each episode of a possible reinfection with the later specimen genetically distinct from that sequenced at first episode</td>
<td>259 confirmed reinfections*</td>
</tr>
<tr>
<td>Persistent infection</td>
<td>Nominally repeat test positives at between 14 and &lt;90-day intervals (likely associated with immunosuppression)</td>
<td>Unquantified</td>
</tr>
</tbody>
</table>

*This is out of 5,014 samples with sequencing data available to end August 2021*
Figure 13: The weekly rate of possible COVID-19 reinfections with cumulation of first infections becoming eligible for reinfection and weekly total of first infection* (England only to week 34 2021)

*These data have been derived independently based on Pillar 1 and Pillar 2 datasets and may therefore differ to previously published data
Respiratory DataMart system (England)

The Respiratory Datamart system was initiated during the 2009 influenza pandemic to collate all laboratory testing information in England. It is now used as a sentinel laboratory surveillance tool, monitoring all major respiratory viruses in England. Sixteen laboratories in England will be reporting data for this season. As this is based on a sample of labs, SARS-CoV-2 positivity figures quoted here will differ from those quoted in the Confirmed COVID-19 cases section, however, they are included to facilitate comparison with data on other respiratory viruses.

In week 40 2021, out of the 108,054 respiratory specimens reported through the Respiratory DataMart System (based on data received from 14 out of 16 laboratories), 2,035 samples were positive for SARS-CoV-2 with an overall positivity of 1.9%. The highest positivity was noted in the 5 to 14-year olds at 10.0% in week 40.

The overall influenza positivity remained very low at 0.6% in week 40, with 15 of the 2,347 samples testing positive for influenza (including 8 influenza A(H3N2), 4 influenza A(not subtyped) and 3 influenza B).

Respiratory syncytial virus (RSV) positivity increased slightly to 8.5% in week 40, with the highest positivity in the under 5-year olds at 20.5%. Rhinovirus positivity decreased from 20.4% in week 39 to 14.8% in week 40. Parainfluenza, adenovirus and human metapneumovirus (hMPV) positivity remained low at 2.0%, 1.6% and 2.9% respectively in week 40 (Figure 16).

Figure 14: DataMart samples positive for influenza and weekly positivity (%) for influenza, England
Figure 15: DataMart weekly positivity (%) for SARS-CoV-2, England

Figure 16: DataMart weekly positivity (%) for other respiratory viruses, England
Figure 17: DataMart weekly positivity (%) for rhinovirus by age, England

Figure 18: DataMart weekly positivity (%) for RSV by age, England
Community surveillance

Acute respiratory infection incidents

Here we present data on acute respiratory infection (ARI) incidents in different settings that are reported to UKHSA Health Protection Teams (HPTs) and entered onto an online web-based platform called HPZone. Incidents are suspected outbreaks of acute respiratory infections linked to a particular setting. All suspected outbreaks are further investigated by the HPT in liaison with local partners. A subset of these will meet the criteria of a confirmed outbreak, that is, where 2 or more laboratory confirmed cases (SARS-CoV-2, influenza or other respiratory pathogens) are linked to a particular setting. Incidents where suspected cases test negative for COVID-19 or other respiratory pathogens, or cases are subsequently found not to have direct links to the setting are discarded.

The number of ARI incidents in each setting with at least one laboratory confirmed case of COVID-19 (or other respiratory pathogen) are reported below. As outlined above, only a subset of these will go on to be confirmed as outbreaks.

Data for England, Scotland and Northern Ireland are included in the UK figures.

Data caveats:

1. The incidents captured on HPZone represent a subset of all ongoing ARI clusters and outbreaks in England rather than an exhaustive listing. A variety of arrangements are in place across UKHSA Centres, with local authorities and other stakeholders supporting HPTs in outbreak investigation in some areas without HPZone reporting. As a result, the number of outbreaks reported for some of the regions are underestimates.

2. For this academic year (2021 to 2022) the thresholds for reporting an outbreak in an educational setting have been revised. Clusters and outbreaks are now reported to the Health protection Team if either of the two following criteria are met:
   - 5 cases or 10% test-confirmed cases of COVID-19 within 10 days (whichever is reached first), among students or staff
   - Evidence of severe illness e.g. students or staff members admitted to hospital or a death as a result of a COVID–19 infection
   - For special education needs schools, residential schools and settings that operate with 20 or fewer children, pupils, students and staff at any one time, clusters and outbreaks are reported if the following criteria is met:
     - 2 children, pupils, students and staff, who are likely to have mixed closely, test positive for COVID-19 within a 10-day period

For more information on managing COVID-19 in educational settings please refer to the framework. This should be taken into consideration when comparing 2021-2022 season data against 2020-2021 season data.
3. It should be noted that the denominator for the different settings will vary significantly. For example, there are fewer hospitals than workplaces. In addition, the propensity to report incidents to UKHSA also varies significantly by setting. This needs to be taken into account when interpreting the weekly number of reported incidents by setting and caution should be used when making comparisons between settings.

4. In light of the above, comparisons between Regions and settings are not advised as they may be misleading.
725 new ARI incidents have been reported in week 40 in the UK (Figure 19):

- 275 incidents were from care homes where 221 had at least one linked case that tested positive for SARS-CoV-2 and 1 for rhinovirus
- 258 incidents were from educational settings where 190 had at least one linked case that tested positive for SARS-CoV-2, and 1 tested positive for RSV
- 28 incidents were from hospitals, where 16 had at least one linked case that tested positive for SARS-CoV-2
- 23 incidents were from workplace settings where 19 had at least one linked case that tested positive for SARS-CoV-2
- 2 incidents were from food outlets or restaurants but no pathogen test results were available
- 5 incidents were from prisons where all had at least one linked case testing positive for SARS-CoV-2
- 134 incidents were from other settings where 98 had at least one linked case that tested positive for SARS-CoV-2

**Figure 19: Number of acute respiratory infection (ARI) incidents by setting, UK**

*Excludes data from Wales*
Figure 20: Number of acute respiratory infection (ARI) incidents by setting, England

Number of ARI incidents vs. Date of report week

- Care home
- Hospital
- Educational settings
- Prison
- Workplace settings
- Food outlet/restaurant
- Other

Figure 21: Number of acute respiratory infection (ARI) incidents in care homes by virus type, England

Care home

Number of ARI incidents vs. Date of report week

- Influenza A
- Influenza B
- SARS-CoV-2
- Rhinovirus
- RSV
- Other respiratory viruses
- No organism reported
Figure 22: Number of acute respiratory infection (ARI) incidents in hospitals by virus type, England

![Hospital chart]

Figure 23: Number of acute respiratory infection (ARI) incidents in educational settings by virus type, England

![Educational settings chart]
Figure 24: Number of acute respiratory infection (ARI) incidents in prisons by virus type, England

Figure 25: Number of acute respiratory infection (ARI) incidents in workplace settings by virus type, England
Figure 26: Number of acute respiratory infection (ARI) incidents in food outlet or restaurant settings by virus type, England

Food outlet/restaurants

- Influenza A
- Influenza B
- SARS-CoV-2
- Rhinovirus
- RSV
- Other respiratory viruses
- No organism reported

Figure 27: Number of acute respiratory infection (ARI) incidents in other settings by virus type from England

Other settings

- Influenza A
- Influenza B
- SARS-CoV-2
- Rhinovirus
- RSV
- Other respiratory viruses
- No organism reported
### Table 2: Total number of situations and incidents by institution and UKHSA Centres over the past 4 weeks with the total number in the last week in brackets

<table>
<thead>
<tr>
<th>UKHSA Centres</th>
<th>Care home</th>
<th>Hospital</th>
<th>Educational settings</th>
<th>Prisons</th>
<th>Workplace settings</th>
<th>Food outlet/restaurant settings</th>
<th>Other settings</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>East of England</td>
<td>74(17)</td>
<td>4(0)</td>
<td>18(5)</td>
<td>1(0)</td>
<td>1(0)</td>
<td>0(0)</td>
<td>37(16)</td>
<td>135(38)</td>
</tr>
<tr>
<td>East Midlands</td>
<td>81(19)</td>
<td>8(4)</td>
<td>105(21)</td>
<td>1(0)</td>
<td>12(6)</td>
<td>2(1)</td>
<td>27(9)</td>
<td>236(60)</td>
</tr>
<tr>
<td>London</td>
<td>39(9)</td>
<td>35(12)</td>
<td>349(70)</td>
<td>1(0)</td>
<td>1(0)</td>
<td>0(0)</td>
<td>27(14)</td>
<td>452(105)</td>
</tr>
<tr>
<td>North East</td>
<td>63(20)</td>
<td>2(1)</td>
<td>5(1)</td>
<td>0(0)</td>
<td>1(0)</td>
<td>0(0)</td>
<td>18(7)</td>
<td>89(29)</td>
</tr>
<tr>
<td>North West</td>
<td>82(25)</td>
<td>4(1)</td>
<td>66(17)</td>
<td>0(0)</td>
<td>24(4)</td>
<td>0(0)</td>
<td>32(8)</td>
<td>208(55)</td>
</tr>
<tr>
<td>South East</td>
<td>103(26)</td>
<td>11(4)</td>
<td>297(60)</td>
<td>6(1)</td>
<td>3(0)</td>
<td>0(0)</td>
<td>28(12)</td>
<td>448(103)</td>
</tr>
<tr>
<td>South West</td>
<td>149(48)</td>
<td>2(1)</td>
<td>134(26)</td>
<td>0(0)</td>
<td>1(1)</td>
<td>0(0)</td>
<td>31(12)</td>
<td>317(88)</td>
</tr>
<tr>
<td>West Midlands</td>
<td>53(24)</td>
<td>9(2)</td>
<td>105(11)</td>
<td>1(0)</td>
<td>6(2)</td>
<td>1(0)</td>
<td>13(3)</td>
<td>188(42)</td>
</tr>
<tr>
<td>Yorkshire and Humber</td>
<td>104(34)</td>
<td>3(2)</td>
<td>70(12)</td>
<td>2(0)</td>
<td>3(1)</td>
<td>0(0)</td>
<td>33(10)</td>
<td>215(59)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>748(222)</td>
<td>78(27)</td>
<td>1149(223)</td>
<td>12(1)</td>
<td>52(14)</td>
<td>3(1)</td>
<td>246(91)</td>
<td>2288(579)</td>
</tr>
</tbody>
</table>
COVID-19 cases by type of residence

Table 3 shows the proportion of confirmed COVID-19 cases according to their type of residence. Property classifications are derived from Ordnance Survey AddressBase and are matched to address details within the laboratory data. Properties are identified by unique property reference number (UPRN) and basic land property unit (BLPU). Cases with poor or no address data which failed the address matching and are classed as ‘undetermined’. No fixed abode and overseas addresses identified by recording in the laboratory data.

In week 40, the highest percentage of confirmed COVID-19 cases by type of residence was seen in residential dwellings (Table 3).

Table 3: Type of residence of confirmed COVID-19 cases by percentage of total weekly cases

<table>
<thead>
<tr>
<th>Type of residence</th>
<th>Week 35</th>
<th>Week 36</th>
<th>Week 37</th>
<th>Week 38</th>
<th>Week 39</th>
<th>Week 40</th>
</tr>
</thead>
<tbody>
<tr>
<td>Residential dwelling (including houses, flats, sheltered accommodation)</td>
<td>95.3</td>
<td>95.3</td>
<td>95.6</td>
<td>96.0</td>
<td>96.1</td>
<td>96.5</td>
</tr>
<tr>
<td>Undetermined</td>
<td>2.5</td>
<td>2.5</td>
<td>2.3</td>
<td>2.0</td>
<td>2.1</td>
<td>1.7</td>
</tr>
<tr>
<td>Care/Nursing home</td>
<td>0.6</td>
<td>0.6</td>
<td>0.5</td>
<td>0.5</td>
<td>0.4</td>
<td>0.5</td>
</tr>
<tr>
<td>Residential institution (including residential education)</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Other property classifications</td>
<td>0.6</td>
<td>0.6</td>
<td>0.6</td>
<td>0.5</td>
<td>0.4</td>
<td>0.5</td>
</tr>
<tr>
<td>House in multiple occupancy (HMO)</td>
<td>0.3</td>
<td>0.3</td>
<td>0.3</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Medical facilities (including hospitals and hospices, and mental health)</td>
<td>0.5</td>
<td>0.4</td>
<td>0.5</td>
<td>0.6</td>
<td>0.6</td>
<td>0.5</td>
</tr>
<tr>
<td>Prisons, detention centres, secure units</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Overseas address</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>No fixed abode</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
</tbody>
</table>
FluSurvey

An internet-based surveillance system has been developed based on FluSurvey. FluSurvey is a web tool survey designed to monitor trends of influenza-like illness (ILI) in the community using self-reported respiratory symptoms from registered participants. The platform has been adapted to capture respiratory symptoms, exposure risk and healthcare seeking behaviours among registered participants to contribute to national surveillance of COVID-19 activity as well as influenza activity since week 44.

Note: ILI is defined as sudden onset of symptoms with at least one of fever (chills); malaise; headache; muscle pain and at least one of cough; sore throat; shortness of breath.

A total of 2,852 participants completed the weekly surveillance survey in week 40, of which 180 (6.3%) reported fever or cough and 68 (2.4%) reported influenza-like illness (ILI). The most commonly used healthcare services reported by respondents remains telephoning a GP practice (Figure 28).
Figure 28: FluSurvey participants self-reporting fever or cough and ILI symptoms, and trends in healthcare seeking behaviour among these participants, England.
FluDetector

FluDetector is a web-based model which assesses internet-based search queries for influenza-like illness (ILI) in the general population.

Daily ILI rate estimates are based on uniformly averaged search query frequencies for a week-long period (including the current day and the six days before it).

For week 40, the daily ILI rate remained low and below the baseline threshold of 19.6 per 100,000 for the 2021 to 2022 season (Figure 29).
Figure 29: Daily estimated ILI Google search query rates per 100,000 population, England
Google search queries

This is a web-based syndromic surveillance system which uses daily search query frequency statistics obtained from the Google Health Trends API. This model focuses on search queries about COVID-19 symptoms as well as generic queries about 'coronavirus' (for example ‘COVID-19’). The search query frequency time series has been weighted based on symptom frequency as reported in other data sources. Frequency of searches for symptoms is compared with a baseline calculated from historical daily data. Further information on this model is available [here](#).

During week 40, the overall and media-debiasing weighted Google search scores remained stable (Figure 30).
Figure 30: Normalised Google search score for COVID-19 symptoms, with weighted score for media-debiasing and historical trend, England
NHS 111

Please note that different syndromic surveillance indicators (NHS 111, GP in hours, GP out of hours and emergency department attendances) are presented here than have been included in previous versions of this report. All indicators previously presented will continue to be published in the Syndromic Surveillance bulletins.

The NHS 111 service monitors daily trends in phone calls made to the service in England, to capture trends in infectious diseases such as influenza and norovirus.

Up to 10 October, NHS 111 calls for cold/flu and cough continued to increase (Figure 31 and 32).

Please note that NHS 111 callers (from 11 May 2020) who are assessed as having probable COVID-19 symptoms are now triaged using symptom specific pathways such as cold or flu, which are included in routine syndromic indicators.

Further information about these caveats is available from the Remote Health Advice Syndromic Surveillance bulletin.
Figure 31: NHS 111 telephony indicators (and 7-day moving average) for number of daily cold/flu calls, England (a) nationally and (b) by age group

(a)

Cold or flu 12/10/2020 - 11/10/2021

Black line is 7 day moving average adjusted for bank holidays. Black dotted line is baseline. Grey columns show weekends and bank holidays.

(b)

Cold or flu by age group (years) 12/10/2020 - 11/10/2021

NOTE: SCALES MAY VARY IN EACH GRAPH TO ENABLE TREND COMPARISON. Black line is 7 day moving average adjusted for bank holidays.
Figure 32: NHS 111 telephony indicators (and 7-day moving average) for number of daily cough calls, England (a) nationally and (b) by age group

(a)

Cough 12/10/2020 - 11/10/2021

Black line is 7 day moving average adjusted for bank holidays.
Black dotted line is baseline. Grey columns show weekends and bank holidays.

(b)

Cough by age group (years) 12/10/2020 - 11/10/2021

NOTE: SCALES MAY VARY IN EACH GRAPH TO ENABLE TREND COMPARISON.
Black line is 7 day moving average adjusted for bank holidays.
Primary care surveillance

RCGP (England)

The weekly ILI consultation rate through the RCGP surveillance was 3.3 per 100,000 registered population in participating GP practices in week 40 compared to 2.1 per 100,000 in the previous week. This is below the baseline threshold (12.2 per 100,000) (Figure 33). By age group, the highest rates were seen in the 0 to 4 year olds (4.9 per 100,000). The Lower Respiratory Tract Infections (LRTI) consultation rate was at 60.9 per 100,000 in week 40, compared to the rate of 54.0 per 100,000 in the previous week. The COVID-19-like indicator consultation rate was at 251.6 per 100,000 in week 40 compared to a rate of 227.4 per 100,000 in the previous week (Figure 34).

Figure 33: RCGP ILI consultation rates, all ages, England
Figure 34: RCGP ILI, LRTI and COVID-19-like indicator consultation rates, England
UK

Overall, weekly ILI consultations rates were below baseline levels in all UK schemes (Table 4).

By age group, the highest rates were seen in the 15 to 44 and 45 to 64-year olds and over in Scotland (1.1 per 100,000) and the 65 to 74 year olds and over in Northern Ireland (3.9 per 100,000).

Table 4: GP ILI consultations in the UK for all ages with MEM thresholds applied

<table>
<thead>
<tr>
<th>GP ILI consultation rates (all ages)</th>
<th>Week number</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40</td>
</tr>
<tr>
<td>England (RCGP)</td>
<td>0.9 0.7 0.5 0.7 0.3 1.0 0.9 0.7 0.7 0.7 0.6 0.6 1.0 1.0 0.8 1.1 1.2 1.7 2.4 3.3</td>
</tr>
<tr>
<td>Wales</td>
<td>0.5 0.0 0.5 0.7 0.3 0.3 0.3 0.5 1.5 0.8 0.3 1.0 0.6 0.9 0.8 2.7 2.3 1.0 2.0 2.8</td>
</tr>
<tr>
<td>Scotland</td>
<td>0.2 0.2 0.3 0.2 0.5 0.4 0.6 0.4 0.3 0.4 0.4 0.3 0.4 0.5 0.7 0.8 0.7 0.9 0.8 0.8</td>
</tr>
<tr>
<td>Northern Ireland</td>
<td>0.5 0.4 0.4 0.6 0.6 0.6 1.0 0.9 0.9 0.9 0.8 0.7 1.0 1.1 0.7 0.7 1.2 0.9 0.5 0.8 1.5</td>
</tr>
</tbody>
</table>

The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity (based on 10 seasons excluding 2009 to 2010), in a standardised approach across Europe. For MEM threshold values for each country, please visit the webpage Sources of UK flu data: influenza surveillance in the UK.
**GP In Hours, Syndromic Surveillance**

The GP In Hours (GPIH) syndromic surveillance system monitors the number of GP visits during regular hours of known clinical indicators.

Up to 10 October, GP in-hours consultations for influenza-like illness remained below baselines (Figure 35).

Further indicators and information about caveats are available from the [GP In Hours Syndromic Surveillance bulletin](#).

**Figure 35:** GPIH clinical indicators for influenza-like illness GP consultations, England (a) nationally, (b) by age group and (c) by UKHSA Centre

(a)
GPIH Baselines are modelled from historical data to give current seasonally expected levels. GP consultations rates decreased during 2020 due to changes in guidance on accessing health care, therefore separate modelled estimates are provided to show seasonally expected levels pre-covid-19.
GP Out of Hours, Syndromic Surveillance

The GP Out of Hours (GPOOH) syndromic surveillance system monitors the numbers of daily unscheduled visits and calls to GPs during evenings, overnight, on weekends and on public holidays. This system covers around 55% of England’s out of hour activity.

Up to 10 October, GP out-of-hours and unscheduled care consultations for acute respiratory infections including influenza-like-illness continued to increase (Figure 36 and 37).

Figure 36: GPOOH number of daily contacts for all ages for influenza-like illness, England

![Graph showing the number of daily contacts for influenza-like illness from 11/10/2020 to 10/10/2021. The graph includes a 7 day moving average adjusted for bank holidays and a baseline. Grey columns indicate weekends and bank holidays.]

Black line is 7 day moving average adjusted for bank holidays.
Black dotted line is baseline. Grey columns show weekends and bank holidays.
Figure 37: GPOOH number of daily contacts for acute respiratory infections, England (a) nationally and (b) by age group

(a) Acute respiratory infection 11/10/2020 - 10/10/2021

Black line is 7 day moving average adjusted for bank holidays. Black dotted line is baseline. Grey columns show weekends and bank holidays.

(b) Acute respiratory infection by age group (years) 11/10/2020 - 10/10/2021

NOTE: SCALES MAY VARY IN EACH GRAPH TO ENABLE TREND COMPARISON. Black line is 7 day moving average adjusted for bank holidays.
Sentinel swabbing scheme in the UK

In week 40 2021, 20 samples tested positive for SARS-CoV-2 with an overall positivity of 21.1% (20 out of 95) compared to 11.7% (14 out of 120) in the previous week, through the UK GP sentinel swabbing schemes (Figure 38).

In week 40, 6 samples tested positive for RSV, with an overall positivity of 9.5% (6 out of 63) compared to 11.5% (10 out of 87) in the previous week.

A graph for influenza will be included when a positive specimen is identified through the scheme.

Samples up to week 41 2020 were only tested for SARS-CoV-2.

Figure 38: Number of positive samples and weekly positivity (%) for (a) COVID-19 and (b) RSV, UK GP sentinel swabbing scheme
*For the most recent week, more samples are expected to be tested therefore the graph in Figure 37 should be interpreted with caution

*Positivity (%) is not calculated when the total number tested is less than 10
Secondary care surveillance

SARI Watch

The Severe Acute Respiratory Infection (SARI) Watch surveillance system was established in 2020 to report the number of laboratory-confirmed influenza and COVID-19 cases admitted to hospital and critical care units (ICU and HDU) in NHS acute trusts across England. This has replaced the USISS Mandatory and Sentinel data collections for influenza surveillance used in previous seasons, and the COVID-19 hospitalisations in England surveillance system (CHESS) collections for COVID-19 surveillance.

The weekly rate of new admissions of COVID-19, influenza and RSV cases is based on the trust catchment population of those NHS Trusts who made a new return. This may differ from other published figures such as the total number of people currently in hospital with COVID-19.

Trends in hospital and critical care admission rates need to be interpreted in the context of testing recommendations.
Hospitalisations, SARI Watch

In week 40, the overall weekly hospital admission rate for COVID-19 remained stable. There were 16 new hospital admissions to sentinel Trusts for influenza (all influenza A(H3N2)) in week 40.

The hospitalisation rate for COVID-19 was at 6.03 per 100,000 in week 40 compared to 5.74 per 100,000 in the previous week.

By UKHSA centre, the highest hospital admission rate for COVID-19 was observed in the North East. By age groups, the highest hospital admission rate for confirmed COVID-19 was in the 85-year olds and over.

Figure 39: Weekly overall hospital admission rates of new COVID-19 and influenza positive cases per 100,000 population reported through SARI Watch, England

* influenza hospital admission rate is reported from week 41 2020 onwards
* influenza hospital admission rate based on 23 sentinel NHS trusts for week 40
* COVID-19 hospital admission rate based on 111 NHS trusts for week 40
* SARI Watch data are provisional
Figure 40: Weekly overall influenza hospital admission rates per 100,000 trust catchment population with MEM thresholds, SARI Watch, England

* the MEM thresholds used are those from the 2019 to 2020 season due to the pandemic

Figure 41: Weekly influenza hospital admissions by influenza type, SARI Watch, England
Figure 42: Weekly hospital admission rate by UKHSA Centre for new (a) COVID-19 positive cases and (b) influenza reported through SARI Watch
Figure 43: Weekly hospital admission rate by age group for new (a) COVID-19 positive cases and (b) influenza reported through SARI Watch

(a)

(b)
ICU or HDU admissions, SARI Watch

In week 40, the overall weekly ICU or HDU admission rates for COVID-19 increased slightly. There were no new ICU or HDU admissions for influenza in week 40.

The ICU or HDU rate for COVID-19 was at 0.46 per 100,000 in week 40 compared to 0.35 per 100,000 in the previous week.

By UKHSA Centre, the highest ICU or HDU admission rates for COVID-19 were observed in the North West. By age groups, the highest ICU or HDU admission rates for COVID-19 were observed in the 85-year olds and over.

Figure 44: Weekly overall ICU or HDU admission rates of new COVID-19 and influenza positive cases per 100,000 population reported through SARI Watch, England

* influenza ICU or HDU admission rate is reported from week 41 2020 onwards
* influenza ICU or HDU admission rate based on 91 NHS trusts for week 40
* COVID-19 ICU or HDU admission rate based on 106 NHS trusts for week 40
* SARI Watch data are provisional
Figure 45: Weekly overall influenza ICU or HDU admission rates per 100,000 trust catchment population with MEM thresholds, SARI Watch, England

Figure 46: Weekly influenza ICU or HDU admissions by influenza type, SARI Watch, England
Figure 47: Weekly ICU or HDU admission rate by UKHSA Centre for new (a) COVID-19 positive cases and (b) influenza, reported through SARI Watch

(a)

(b)
Figure 48: Weekly ICU or HDU admission rate by age group for new (a) COVID-19 positive cases and (b) influenza, reported through SARI Watch.
ECMO, SARI Watch

From week 41 2020, a total of 371 laboratory confirmed COVID-19 admissions have been reported from the 6 Severe Respiratory Failure (SRF) centres in the UK.
There were no new laboratory confirmed COVID-19 admission reported in week 40 (Figure 49).

Figure 49: Laboratory confirmed ECMO admissions (COVID-19, influenza and non-COVID-19 confirmed) to Severe Respiratory Failure centres in the UK

* SARI Watch data are provisional
**RSV admissions, SARI Watch**

Data on hospitalisations, including ICU/HDU admissions, with Respiratory Syncytial Virus (RSV) are shown below. RSV SARI Watch surveillance is sentinel.

**Figure 50: Weekly overall hospital admission rates (including ICU/HDU) of RSV positive cases per 100,000 population reported through SARI Watch, England**

* Please note that in previous seasons, RSV SARI Watch surveillance has run from week 40 to week 20. In the 2020 to 2021 season this was extended to run throughout the year, to allow for surveillance of out-of-season trends.
Figure 51: Weekly hospitalisation (including ICU/HDU) admission rates by age group for new RSV cases reported through SARI Watch in 2020 to 2021, England

* Please note that rates are based on the number of hospitalised cases divided by the Trust catchment population, multiplied by 100,000
*SARI Watch data are provisional
Emergency Department attendances, Syndromic surveillance

The Emergency Department Syndromic Surveillance System (EDSSS) monitors the daily visits in a network of emergency departments across England.

Up to 10 October 2021, the daily number of ED attendances as reported by 106 EDs for COVID-19-like infection and for acute respiratory infection increased (Figure 52).

Please note: the COVID-19-like ED indicator is an underestimation of the number of COVID-19 attendances as it only includes attendances with a COVID-19-like diagnosis as their primary diagnosis. The EDSSS COVID-19-like indicator should therefore be used to monitor trends in ED attendances and not to estimate actual numbers of COVID-19 ED attendances. Further information about these caveats is available from the Emergency Department Syndromic Surveillance bulletin.

Figure 52: Daily ED attendances for COVID-19-like infections, England (a) nationally, (b) by age group and (c) by UKHSA Centre

(a)
Weekly National Influenza and COVID-19 Report: week 41 report (up to week 40 data)

(b) Covid-19-like by age group (years) 11/10/2020 - 10/10/2021

- under 1
- 1 to 4
- 5 to 14
- 15 to 44
- 45 to 64
- over 65

Daily attendances

NOTE: SCALES MAY VARY IN EACH GRAPH TO ENABLE TREND COMPARISON.
Black line is 7 day moving average adjusted for bank holidays.

(c) Covid-19-like by region 11/10/2020 - 10/10/2021

- North East
- North West
- Yorkshire and Humber
- East Midlands
- West Midlands
- East of England
- London
- South East
- South West

Daily attendances

NOTE: SCALES MAY VARY IN EACH GRAPH TO ENABLE TREND COMPARISON.
Black line is 7 day moving average adjusted for bank holidays.
Figure 53: Daily ED attendances for acute respiratory infections, England (a) nationally, (b) by age group and (c) by UKHSA Centre

(a)

Acute respiratory infection 11/10/2020 - 10/10/2021

Black line is 7 day moving average adjusted for bank holidays.
Black dotted line is baseline. Grey columns show weekends and bank holidays.

(b)

Acute respiratory infection by age group (years) 11/10/2020 - 10/10/2021

NOTE: SCALES MAY VARY IN EACH GRAPH TO ENABLE TREND COMPARISON.
Black line is 7 day moving average adjusted for bank holidays.
Acute respiratory infection by region 11/10/2020 - 10/10/2021

NOTE: SCALES MAY VARY IN EACH GRAPH TO ENABLE TREND COMPARISON.
Black line is 7 day moving average adjusted for bank holidays.
Black dotted line is baseline.
Mortality surveillance

Cumulative COVID-19 deaths

Changes to the definitions of COVID-19 related deaths in England are described in more detail in an accompanying technical summary.

The current definitions used for mortality surveillance of COVID-19 in England are:

(a) 28 day definition: A death in a person with a laboratory-confirmed positive COVID-19 test and died within (equal to or less than) 28 days of the first positive specimen date

(b) 60 day definition: A death in a person with a laboratory-confirmed positive COVID-19 test and either: died within 60 days of the first specimen date OR died more than 60 days after the first specimen date only if COVID-19 is mentioned on the death certificate

The introduction of these definitions will affect the numbers which have been presented in past reports and therefore Figure 54 represents these differences by definition.

Figure 54: Number of deaths since by week of death and time since laboratory confirmation of COVID-19, England

*The data are shown by the week of death. This gives the most accurate analysis of this time progression, however, for the most recent weeks’ numbers more deaths are expected to be registered therefore this should be interpreted with caution*
Figure 55: Age-sex pyramid of laboratory confirmed COVID-19 deaths, for the past year

Table 5: Ethnic group (%) of COVID-19 deaths and time since laboratory confirmation of COVID-19, England, for the past year

<table>
<thead>
<tr>
<th>Ethnicity</th>
<th>28 day definition</th>
<th>60 day definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>88.8</td>
<td>88.8</td>
</tr>
<tr>
<td>Asian / Asian British</td>
<td>7.3</td>
<td>7.3</td>
</tr>
<tr>
<td>Black / African / Caribbean / Black British</td>
<td>2.9</td>
<td>2.9</td>
</tr>
<tr>
<td>Mixed / Multiple ethnic groups</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Other ethnic group</td>
<td>0.5</td>
<td>0.5</td>
</tr>
</tbody>
</table>
Table 6: Cumulative number of COVID-19 deaths since and time since laboratory confirmation of COVID-19 by UKHSA Centres, for the past year

<table>
<thead>
<tr>
<th>UKHSA Centres</th>
<th>28 day definition</th>
<th>60 day definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>North East</td>
<td>4,313</td>
<td>5,143</td>
</tr>
<tr>
<td>North West</td>
<td>12,741</td>
<td>15,249</td>
</tr>
<tr>
<td>Yorkshire and Humber</td>
<td>8,291</td>
<td>9,840</td>
</tr>
<tr>
<td>West Midlands</td>
<td>9,788</td>
<td>11,732</td>
</tr>
<tr>
<td>East Midlands</td>
<td>7,862</td>
<td>9,348</td>
</tr>
<tr>
<td>East of England</td>
<td>10,297</td>
<td>12,180</td>
</tr>
<tr>
<td>London</td>
<td>10,224</td>
<td>12,338</td>
</tr>
<tr>
<td>South East</td>
<td>12,644</td>
<td>15,019</td>
</tr>
<tr>
<td>South West</td>
<td>5,549</td>
<td>6,493</td>
</tr>
</tbody>
</table>
Figure 56: Cumulative mortality rate of COVID-19 cases per 100,000 population tested under Pillars 1 and 2 for the past 4 weeks by (a) 28 day definition and (b) 60 day definition

(a)
Weekly National Influenza and COVID-19 Report: week 41 report (up to week 40 data)

(b)

![Map](image)

From the week of 9th August 2021, incidence rate calculations by UTLA will use 2020 ONS mid-year population estimates.
Daily excess all-cause mortality (England)

Deaths occurring from 1 January 2020 to 6 October 2021 were assessed to calculate the daily excess above a baseline using age-group and region specific all cause deaths as provided daily by the General Register Office (GRO). The deaths were corrected to allow for delay to registration based on past data on these delays and the baseline was from the same day of the year in the previous 5 years plus or minus 7 days with an extrapolated time trend, and with 2 and 3 standard deviation (SD) limits shown (Figure 57).

Weeks in which at least 2 days exceeded the 3SD threshold are shown in Table 7 and the daily difference from the baseline by age and region is given in Figure 56.

Note that as these data are by date of death with delay corrections, numbers are subject to change each week, particularly for more recent days.

The current week’s model supersedes models presented in previous week.

No excess all-cause mortality was observed in week 39, overall, by age or sub-nationally. Week 36 2021 included a heatwave period of three days with high temperatures (mean Central England Temperature >20c) which may have contributed to the excess seen in this week. The excess mortality noted in week 33 2020 and week 29 2021 coincide with heat waves (Figure 57, 58 and Table 7).
Figure 57: Daily excess all-cause deaths in all ages, England, 1 January 2020 to 6 October 2021

^Baseline calculation:
January to November 2020: same day in previous 5 years plus or minus 1 week with a linear trend.
December 2020 to February 2021: past 3 low flu years plus or minus 2 weeks, no trend.
March 2021 onwards: same baseline as 2020
* corrected for delay to registration from death
Other measures of excess mortality published by UKHSA are the Fingertips excess mortality in England report, which uses ONS death registration data; and the all-cause mortality surveillance report, which uses the EuroMOMO model to measure excess deaths.

Table 7: Excess all-cause deaths by (a) age group and (b) UKHSA centres, England

(a)

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Excess detected in week 39 2021?</th>
<th>Weeks in excess from week 10 to 53 2020</th>
<th>Weeks in excess from week 01 to 39 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>x</td>
<td>13 to 21, 33, 43, 45, 50, 52 to 53</td>
<td>01 to 07, 31 to 33, 35 to 36</td>
</tr>
<tr>
<td>under 25</td>
<td>x</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>25 to 44</td>
<td>x</td>
<td>14 to 16</td>
<td>32, 37</td>
</tr>
<tr>
<td>45 to 64</td>
<td>x</td>
<td>12 to 19, 49 to 50, 52 to 53</td>
<td>01 to 08, 29 to 30, 32, 36</td>
</tr>
<tr>
<td>65 to 74</td>
<td>x</td>
<td>13 to 19, 46, 48, 52 to 53</td>
<td>01 to 07, 36</td>
</tr>
<tr>
<td>75 to 84</td>
<td>x</td>
<td>13 to 21, 33, 45, 49, 52 to 53</td>
<td>01 to 07, 32, 36</td>
</tr>
<tr>
<td>85+</td>
<td>x</td>
<td>13 to 21, 33, 53</td>
<td>01 to 07, 36</td>
</tr>
</tbody>
</table>

(b)

<table>
<thead>
<tr>
<th>UKHSA Centres</th>
<th>Excess detected in week 39 2021?</th>
<th>Weeks in excess from week 10 to 53 2020</th>
<th>Weeks in excess from week 01 to 39 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>East of England</td>
<td>x</td>
<td>14 to 19, 52, 53</td>
<td>01 to 07</td>
</tr>
<tr>
<td>East Midlands</td>
<td>x</td>
<td>13 to 19, 48</td>
<td>01 to 07</td>
</tr>
<tr>
<td>London</td>
<td>x</td>
<td>12 to 19, 33, 52 to 53</td>
<td>01 to 06, 36</td>
</tr>
<tr>
<td>North East</td>
<td>x</td>
<td>14 to 21</td>
<td>02 to 04</td>
</tr>
<tr>
<td>North West</td>
<td>x</td>
<td>13 to 19, 33, 42 to 47</td>
<td>01 to 07, 32, 35 to 36</td>
</tr>
<tr>
<td>South East</td>
<td>x</td>
<td>13 to 21, 33, 50 to 53</td>
<td>01 to 07, 36</td>
</tr>
<tr>
<td>South West</td>
<td>x</td>
<td>13 to 19, 33</td>
<td>01 to 07, 29, 36</td>
</tr>
<tr>
<td>West Midlands</td>
<td>x</td>
<td>13 to 20, 45, 48</td>
<td>01 to 07, 29, 36</td>
</tr>
<tr>
<td>Yorkshire and Humber</td>
<td>x</td>
<td>14 to 21, 23, 43 to 50</td>
<td>02 to 04, 32, 35 to 36</td>
</tr>
</tbody>
</table>
Figure 58: Daily excess all-cause deaths by (a) age group and (b) UKHSA centres, England, 1 March 2020 to 6 October 2021
Microbiological surveillance

Virus characterisation

UKHSA characterises the properties of influenza viruses through one or more tests, including genome sequencing (genetic analysis) and haemagglutination inhibition (HI) assays (antigenic analysis). These data are used to compare how similar the currently circulating influenza viruses are to the strains included in seasonal influenza vaccines, and to monitor for changes in circulating influenza viruses. The interpretation of genetic and antigenic data sources is complex due to a number of factors, for example, not all viruses can be cultivated in sufficient quantity for antigenic characterisation, so that viruses with sequence information may not be able to be antigenically characterised as well. Occasionally, this can lead to a biased view of the properties of circulating viruses, as the viruses which can be recovered and analysed antigenically, may not be fully representative of majority variants, and genetic characterisation data does not always predict the antigenic characterisation.

In week 40 2021, the UKHSA Respiratory Virus Unit genetically characterised three influenza A(H3N2) viruses, which were detected in weeks 35, 37 and 38 respectively, after the lifting of legal restrictions on social contact in England on July 19th, 2021. Sequencing of the haemagglutinin (HA) gene shows that these viruses belong in the genetic subclade 3C.2a1b, within a cluster designated 3C.2a1b.2a2. The Northern Hemisphere 2021/22 influenza A(H3N2) vaccine strain (an A/Cambodia/e0826360/2020-like virus) also belongs in genetic subclade 3C.2a1b, within the 2a1 genetic group.

One influenza B virus, which was detected in week 37 2021, has been genetically characterised to date and belongs in genetic clade 1A.3 of the B/Victoria lineage, characterised by deletion of three amino acids in the HA, in a subgroup designated 1A.3a2. The N. Hemisphere 2021/22 B/Victoria-lineage quadrivalent and trivalent vaccine component virus (a B/Washington/02/2019-like virus) belongs in genetic clade 1A.3.

No influenza A(H1N1)pdm09 influenza viruses have been characterised to date this season. The early detection of A(H3N2) and influenza B is in accordance with predominant detections internationally over the period of August and September 2021.

At this early stage of the influenza season, it is too early to predict which influenza lineages will dominate throughout the season, and a close watch will be kept on the proportion of different viruses circulating to assist with the evaluation of vaccine effectiveness.
Antiviral susceptibility

Influenza positive samples are screened for mutations in the virus neuraminidase gene known to confer oseltamivir and/or zanamivir resistance. Additionally, testing of certain influenza A(H1N1)pdm09, A(H3N2), and influenza B virus isolates for neuraminidase inhibitor susceptibility (oseltamivir and zanamivir) may be performed at UKHSA-RVU using a functional assay. The data summarized below combine the results of both testing methods, if undertaken. The samples tested are routinely obtained for surveillance purposes, but diagnostic testing of patients suspected to be infected with neuraminidase inhibitor-resistant virus is also performed.

SARS-CoV-2 variants

UKHSA conducts surveillance of SARS-CoV-2 variants. Further information including an overview of variants, information on new variants and detailed surveillance of particular variants of concern can be found on GOV.UK and in the latest technical briefing.
Antimicrobial susceptibility

Table 8 shows in the 12 weeks up to week 40 2021, the proportion of all lower respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenza, Staphylococcus aureus, MRSA and MSSA tested and susceptible to antibiotics. These organisms are the key causes of community-acquired pneumonia (CAP) and the choice of antibiotics reflects the British Thoracic Society empirical guidelines for management of CAP in adults.

Table 8: Antimicrobial susceptibility surveillance in lower respiratory tract

<table>
<thead>
<tr>
<th>Organism</th>
<th>Antibiotic</th>
<th>Specimens tested (N)</th>
<th>Specimens susceptible (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. pneumoniae</td>
<td>Penicillin</td>
<td>1,282</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>1,423</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>1,383</td>
<td>81</td>
</tr>
<tr>
<td>H. influenzae</td>
<td>Amoxicillin/ampicillin</td>
<td>5,748</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Co-amoxiclav</td>
<td>6,419</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>1,726</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>6,532</td>
<td>98</td>
</tr>
<tr>
<td>S. aureus</td>
<td>Methicillin</td>
<td>4,394</td>
<td>93</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>5,026</td>
<td>71</td>
</tr>
<tr>
<td>MRSA</td>
<td>Clindamycin</td>
<td>245</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>277</td>
<td>69</td>
</tr>
<tr>
<td>MSSA</td>
<td>Clindamycin</td>
<td>3,192</td>
<td>78</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>3,821</td>
<td>93</td>
</tr>
</tbody>
</table>

* Macrolides = erythromycin, azithromycin and clarithromycin

Data source: UKHSA’s SGSS AMR module, please note that this is different to the data source used in the reports published between weeks 41 2020 to 05 2021 inclusive of the 2020 to 2021 influenza season when the SGSS CDR module was used instead due to a UKHSA SGSS AMR data infrastructure issue which has now been resolved. Therefore, the above results are not directly comparable to the results reported between weeks 41 2020 and 05 2021. The AMR module of SGSS was used during the 2019 to 2020 influenza season. There has been a reduction in the total number of bacterial positive lower respiratory tract clinical samples reported to UKHSA since mid-March 2020.
COVID-19 sero-prevalence surveillance

The results from testing samples provided by healthy adult blood donors aged 17 years and older, supplied by the NHS Blood and Transplant (NHS BT collection) between weeks 35 2020 and week 39 2021 are summarised. This programme has previously involved testing approximately 1,000 donor samples from 2 different NHS regions each week. As of week 44 2020, approximately 250 samples from each geographic NHS region are tested each week. The COVID-19 vaccination campaign began on the 8 December 2020 (week 50) with a phased rollout by age and risk group.

Seroprevalence in Adults aged 17 years and older (Blood Donors)

The results presented here are based on testing blood donor samples with Roche nucleoprotein (N) and Roche spike (S) antibody assays.

Nucleoprotein (Roche N) assays only detect post-infection antibodies, whereas spike (Roche S) assays will detect both post-infection antibodies and vaccine-induced antibodies. Thus, changes in seropositivity for the Roche N assay will reflect the effect of natural infection. Increases in seropositivity as measured by S antibody will reflect both infection and vaccination. Antibody responses to both targets will reflect infection or vaccination occurring at least 2 to 3 weeks previously given the time taken to generate a COVID-19 antibody response. Donors have been asked to defer donations for at least 7 full days post vaccination.

This report presents Roche N and Roche S seropositivity estimates on the same set of samples, using a 4-week rolling prevalence for national and age group estimates and a 12-week rolling prevalence for regional estimates. Seroprevalence estimates reported are based on seropositivity which are unadjusted for the sensitivity and specificity of the assays used.

National prevalence

Overall population weighted (by age group, sex and NHS region) antibody prevalence among blood donors aged 17 years and older in England was 19.7% (95% CI 18.7% - 20.8%) using the Roche N assay and 98.1% (95% CI 97.7% - 98.5%) using the Roche S assay for the period 6 September to 1 October (weeks 36 to 39 2021). 1,359 out of 7,074 were Roche N positive and 6,950 out of 7,073 sample were Roche S positive. This compares with 18.8% (95% CI 17.8% - 19.9%) Roche N seropositivity and 97.7% (95% CI 97.2% - 98.1%) Roche S seropositivity for the period of 12 August to 5 September 2021 (weeks 32 to 35 2021).

Seropositivity (weighted by region, age group and sex) varies over time. Figure 59 shows the overall 4-weekly rolling proportion seropositive over time for the Roche N and Roche S assays. Seropositivity estimates are plotted weekly using the mid-point of a rolling 4-weekly period.
Regional prevalence of infection over time

Seropositivity (weighted by age group and sex) using the Roche N assay which detects infection only, varies by region (Figure 60).

Regional seropositivity estimates are plotted using the mid-point of a 12-weekly rolling period that reduces to 8 weekly in the most recent weeks to allow for a more representative current estimate of seropositivity. Previously, regional Roche N seropositivity was reported using a 4-week rolling period; however, this was changed due to the difficulty interpreting regional trends when using a 4-weekly window, given the fluctuation in sampling locations each week for some regions.

In London, the 12-weekly rolling seropositivity increased from 24.9% (95% CI 23.4% - 26.4%) in weeks 20 to 31 2021 to 27.0% (95% CI 25.1% - 29.1%) in weeks 32 to 39 2021.

Data from the Midlands show the proportion seropositive increased from 15.9% (95% CI 14.7% - 17.3%) in weeks 20 to 31 2021 to 18.9% (95% CI 17.0% - 21.0%) in weeks 32 to 39 2021.

Seropositivity in the North East and Yorkshire region increased from 15.3% (95% CI 14.0% - 16.8%) in weeks 20 to 31 2021 to 19.4% (95% CI 17.5% - 21.5%) in weeks 32 to 39 2021.

Testing of samples from the North East was incomplete at the time of publication. This is not expected to alter interpretation of trends and estimates will be updated in next week’s report.

Data from the North West show that seropositivity has increased from 21.1% (95% CI 19.5% - 22.8%) in weeks 20 to 31 2021 to 24.0% (95% CI 22.1% - 26.0%) in weeks 32 to 39 2021.

Seropositivity increased in the South East region from 12.4% (95% CI 11.2% - 13.7%) in weeks 20 to 31 2021 to 14.7% (95% CI 13.2% - 16.4%) in weeks 32 to 39 2021.

In the South West region, seropositivity increased from 8.9% (95% CI 7.9% - 10.1%) in weeks 20 to 31 2021 to 12.8% (95% CI 11.3% - 14.5%) in weeks 32 to 39 2021.

In the East of England, seropositivity increased from 13.3% (95% CI 12.1% - 14.6%) in weeks 20 to 31 2021 to 15.9% (95% CI 14.3% - 17.6%) in weeks 32 to 39 2021.

London has consistently seen the highest Roche N seropositivity with the lowest observed in the South West.

Prevalence by age group

Seropositivity estimates by age group using the Roche N and Roche S assays are presented below. Prevalence for all age groups for weeks 41 to 44 has been excluded due to a change in sampling strategy from week 44 which resulted in a small number of samples from older age groups in some regions which makes interpretation of trends for this period difficult.

Based on testing samples using the Roche N assay (Figure 61) as a marker of infection, the highest seropositivity has consistently been observed in those aged 17 to 29 and the lowest in those aged 70 to 84.
Increases in Roche N seropositivity have recently been observed in 30 to 39-year olds from 21.1% (95% CI 18.8% - 23.5%) in weeks 32 to 35 to 25.2% (95% CI 22.8% - 27.7%) in weeks 36 to 39 and in individuals aged 60 to 69 from 11.9% (95% CI 10.2% – 13.9%) in weeks 32 to 35 to 14.2% (95% CI 12.3% - 16.4%) in weeks 36 to 39. Small increases were also seen in the 50 to 59 year olds from 17.7% (95% CI 16.0% - 19.7%) in weeks 32 to 35 to 18.8% (95% CI 16.9% - 20.8%) in weeks 36 to 39. Prevalence in those aged 40 to 49 years old slightly decreased from 20.7% (95% CI 18.4% - 23.1%) in weeks 32 to 35 to 19.5% (95% CI 17.5% - 21.8%) in weeks 36 to 39. Prevalence in individuals aged 17 to 29 has remained stable at 28.8% (95% CI 25.7% - 32.2%) in weeks 32 to 35 and 28.0% (95% CI 24.9% - 31.3%) in weeks 36 to 39 as well as in individuals aged 70 to 84 between 7.1% (95% CI 5.1% - 9.8%) in weeks 32 to 35 and 7.6% (95% CI 5.5% - 10.3%) in weeks 36 to 39. Decreases in Roche N seropositivity may be due to waning of the N antibody response over time; however it’s important to note that confidence intervals overlap.

The sharp increases in seropositivity across all age groups using the Roche S assay reflect the presence of antibodies induced by vaccination (Figure 61).

Roche S seropositivity increased earliest in those aged 70 to 84 and since week 13 plateaued, reaching 99.2% (95% CI 98.0% - 99.7%) in weeks 36 to 39 2021. Seropositivity in those aged 60 to 69 has also plateaued since week 16 reaching 98.9% (95% CI 98.1% - 99.4%) in weeks 36 to 39 2021. A plateauing in Roche S seropositivity since week 19 has been observed in those aged 50 to 59 reaching 98.4% (95% CI 97.7% - 98.9%) in weeks 36 to 39 2021. A plateauing in seropositivity has been observed in the 40 to 49-year olds since week 23 reaching 98.2% (95% CI 97.4% – 98.8%) in weeks 36 to 39. Plateauing has been observed in the 30 to 39-year olds from week 28 reaching 97.7% (95% CI 96.6% - 98.4%) in weeks 36 to 39. A plateauing in seropositivity has recently been observed in the 17 to 29-year olds reaching 97.0% (95% CI 95.4% - 98.0%) in weeks 36 to 39 2021.

Seropositivity estimates for S antibody in blood donors are likely to be higher than would be expected in the general population and this probably reflects the fact that donors are more likely to be vaccinated. Seropositivity estimates for N antibody will underestimate the proportion of the population previously infected due to (i) blood donors are potentially less likely to be exposed to natural infection than age matched individuals in the general population (ii) waning of the N antibody response over time and (iii) recent observations from UKHSA surveillance data that N antibody titres appear to be lower in individuals who acquire infection following two doses of vaccination.

Vaccination has made an important contribution to the overall Roche S increases observed since the roll out of the vaccination programme, initially amongst individuals aged 50 years and above who were prioritised for vaccination as part of the phase 1 programme and more recently in younger adults as part of phase 2 of the vaccination programme. Roche S seropositivity is now >95% across all adult age groups.
Figure 59: Overall 4-weekly rolling SARS-CoV-2 antibody seroprevalence (% seropositive) in blood donors

Figure 60: 12-weekly rolling SARS-CoV-2 antibody seroprevalence (% seropositive) in blood donors by region, using Roche N test; error bars show 95% confidence intervals
Figure 61: Population weighted 4-weekly rolling SARS-CoV-2 antibody seroprevalence (% seropositive) in blood donors from the Roche S and Roche N assays by a) age groups 17 to 29, 30 to 39 and 40 to 49, b) age group 50 to 59, 60 to 69 and 70 to 84.
Influenza vaccination

Influenza vaccine uptake in GP patients

Up to week 40 2021 in 40.2% of GP practices reporting weekly to ImmForm for the main collection, the provisional proportion of people in England who had received the 2021 to 2022 influenza vaccine in targeted groups was as follows:

- 14.3% in under 65 years in a clinical risk group
- 11.1% in all pregnant women
- 36.1% in all 65 year olds and over
- 36.9% in 65 year olds and over and in a clinical risk group
- 10.9% in those aged 50 to 64 who are NOT in a clinical risk group

Weekly vaccine coverage data are provisional.

In 2021 to 2022, all 2 and 3 year olds continue to be eligible for influenza vaccination through their GPs. Up to week 40 2021, in 58.1% of GP practices reporting weekly to ImmForm for the childhood collection, the provisional proportion of children in England who had received the 2021 to 2022 influenza vaccine in targeted groups was as follows:

- 13.2% in all 2 year olds
- 14.0% in all 3 year olds
COVID-19 vaccination

COVID-19 vaccine uptake in England

COVID-19 vaccinations began in England on 8 December 2020 during week 50 2020 (week ending 13 December 2020). Cumulative data up to week 41 2021 (week ending 10 October 2021) was extracted from the National Immunisation Management Service (NIMS). The data presented this week is the provisional proportion of people in England who had received one dose and two doses of a COVID-19 vaccination by age group. The overall vaccine uptake in the population for dose 1 was 65.5% and 60.4% for dose 2. The breakdown by sex showed vaccine uptake in males was 63.0% and 67.8% in females for dose 1. For dose 2 total uptake was 57.9% in males and 63.0% in females. The vaccine uptake rate in adults aged 18 and over was 80.0% (39,739,281/49,645,489) for dose 1 and 75.4% (37,446,625/49,645,489) for dose 2.

Table 9: Provisional cumulative COVID-19 vaccine uptake by age in England

<table>
<thead>
<tr>
<th>NATIONAL</th>
<th>Vaccinated with at least 1 dose</th>
<th>Vaccinated with 2 doses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>People in NIMS cohort</td>
<td>Number vaccinated</td>
</tr>
<tr>
<td>Over 80</td>
<td>2,730,254</td>
<td>2,604,619</td>
</tr>
<tr>
<td>75 to under 80</td>
<td>2,063,584</td>
<td>1,972,331</td>
</tr>
<tr>
<td>70 to under 75</td>
<td>2,862,229</td>
<td>2,707,597</td>
</tr>
<tr>
<td>65 to under 70</td>
<td>2,887,183</td>
<td>2,670,362</td>
</tr>
<tr>
<td>60 to under 65</td>
<td>3,451,453</td>
<td>3,128,912</td>
</tr>
<tr>
<td>55 to under 60</td>
<td>4,081,620</td>
<td>3,629,035</td>
</tr>
<tr>
<td>50 to under 55</td>
<td>4,235,139</td>
<td>3,666,322</td>
</tr>
<tr>
<td>45 to under 50</td>
<td>4,014,772</td>
<td>3,298,012</td>
</tr>
<tr>
<td>40 to under 45</td>
<td>4,145,545</td>
<td>3,177,496</td>
</tr>
<tr>
<td>35 to under 40</td>
<td>4,539,021</td>
<td>3,233,237</td>
</tr>
<tr>
<td>30 to under 35</td>
<td>4,792,524</td>
<td>3,205,596</td>
</tr>
<tr>
<td>25 to under 30</td>
<td>4,504,624</td>
<td>2,906,115</td>
</tr>
<tr>
<td>20 to under 25</td>
<td>3,977,899</td>
<td>2,606,612</td>
</tr>
<tr>
<td>18 to under 20</td>
<td>1,359,642</td>
<td>933,035</td>
</tr>
<tr>
<td>16 to under 18</td>
<td>1,361,666</td>
<td>770,022</td>
</tr>
<tr>
<td>12 to under 16</td>
<td>2,852,937</td>
<td>335,879</td>
</tr>
<tr>
<td>Under 12</td>
<td>8,565,426</td>
<td>21,948</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>62,425,518</strong></td>
<td><strong>40,867,571</strong></td>
</tr>
</tbody>
</table>

*Caution should be exercised when summing the regional or age figures as the sum of the regions will not equal the England total. This is due to individuals vaccinated in England who have a registered address in Scotland or Wales or where their address is unknown. There were also vaccinations where the individual had an unknown region and age group.

Data are provisional and subject to change following further validation checks. Any changes to historic figures will be reflected in the most recent publication. Please note that numbers published by UKHSA are for public health surveillance purposes only.
Figure 62: Cumulative weekly COVID-19 vaccine uptake by age in England for (a) Dose 1 and (b) Dose 2

(a)

(b)
Figure 63: Age-Sex pyramid for COVID-19 vaccine uptake by age in England for Dose 1

% Vaccine Uptake (Dose 1)

Figure 64: Age-Sex pyramid for COVID-19 vaccine uptake by age in England for Dose 2

% Vaccine Uptake (Dose 2)
From the 6 January 2021 (week 1 2021), the JCVI advises initially prioritising delivery of the first vaccine dose to maximise the public health impact in the short term and reduce the number of preventable deaths from COVID-19. See statement.

For UK COVID-19 daily counts of vaccinations, please see the Vaccinations’ section of the UK COVID-19 dashboard.

For COVID-19 management information on the number of COVID-19 vaccinations provided by the NHS in England, please see the COVID-19 vaccinations webpage.
International update

Global COVID-19 update

Globally, up to 12 October 2021, a total of 238,008,135 cases of COVID-19 infection have been reported worldwide, including 4,855,354 COVID-19 related deaths.

For further information on the global COVID-19 situation please see the WHO COVID-19 situation reports.

Figure 6: Global map of cumulative COVID-19 cases
Figure 67: Global map of change in weekly COVID-19 case incidence rate per 100,000 population compared to the previous week
Global influenza update

Updated on 27 September 2021 (based on data up to 12 September 2021) [WHO website].

In the temperate zones of the northern hemisphere, influenza activity remained below baseline overall. In the temperate zone of the southern hemisphere, influenza activity was reported at inter-seasonal levels. Worldwide, influenza A and B viruses were detected in similar proportions.

In the Caribbean and Central American countries, sporadic influenza B virus detections were reported in some countries.

In tropical South America, one influenza A detection was reported in Peru this period.

In Western Africa, a few influenza A(H1N1)pdm09 virus detections were reported in Burkina Faso, Ghana and Mali. Ghana also reported influenza A(H3N2) detections. Senegal reported detections of influenza A viruses. SARI activity was high in Togo but no influenza detections were reported.

In Middle Africa, Cameroon reported a few influenza A(H1N1)pdm09 and one influenza B/Victoria lineage detection.

In Eastern Africa, influenza A(H1N1)pdm09 detections were reported in Tanzania. Influenza A(H3N2) viruses were reported in Ethiopia, Kenya and Tanzania. Influenza B viruses (Victoria lineage for those where lineage was determined) were reported in Kenya and Mozambique. ILI rates remained elevated in Zambia.

In Southern Asia, influenza detections of predominantly A(H3N2) and influenza B/Victoria lineage viruses continued to be reported in India and Nepal, though showing a decreasing trend. In addition, a few influenza A(H1N1)pdm09 detections were reported in India. Sporadic detections of influenza A(H3N2) viruses were reported in Pakistan.

In South East Asia, a few influenza A(H3N2) virus detections were reported in the Philippines in recent weeks. In Lao People’s Democratic Republic, ILI and SARI levels remained below the average of the previous three years.

In the countries of North America, influenza activity indicators, including the percent of tests positive for influenza and influenza like illness (ILI) activity, were at low levels with sporadic detections of influenza A and B viruses.
In Europe, influenza activity remained at inter-seasonal levels with detections of influenza A (predominated A(H3N2) for those specimens that were subtyped) and B viruses reported in some countries.

In Central Asia, no influenza detections were reported across reporting countries in this period.

In Northern Africa, no reports were received for this reporting period.

In Western Asia, Lebanon, Oman and Qatar reported influenza A(H3N2) virus detections.

In East Asia, influenza illness indicators and influenza activity remained low.

The WHO GISRS laboratories tested more than 275,940 specimens during the period 30 August to 12 September 2021. A total of 1884 specimens were positive for influenza viruses, of which 808 (42.9%) were typed as influenza A and 1076 (57.1%) as influenza B. Of the sub-typed influenza A viruses, 54 (7.3%) were influenza A(H1N1)pdm09 and 686 (92.7%) were influenza A(H3N2). Of the characterized B viruses, 973 (99.8%) belonged to the B-Victoria lineage and 2 (0.2%) to the B-Yamagata lineage.

**Influenza in Europe**


For week 39 of 2021, influenza activity remained at inter-seasonal levels throughout Europe, with an increase in A(H3) detections.

For week 39 2021, of 492 sentinel specimens tested for influenza viruses, 5 were positive.

**Influenza in the Northern Hemisphere**

For further information on influenza in the United States of America please see the [Centre for Disease Control weekly influenza surveillance report](https://www.cdc.gov/flu/weekly/).

For further information on influenza in Canada please see the [Public Health Agency weekly influenza report](https://www.canada.ca/en/public-health/services/publications/influenza-influenza-report/).
Other respiratory viruses

Avian influenza

On 28 September 2021, one new case of human infection with avian influenza A(H5N6) virus, with an onset of 14 August 2021, was reported from the National Health Commission of the People’s Republic of China to WHO in the Western Pacific Region. To date, a total of 48 laboratory-confirmed cases of human infection with influenza A(H5N6) virus including 25 deaths have been reported to WHO in the Western Pacific Region since 2014. Prior to this, the last three cases were reported from China, with onset dates of 23 August 2021, 13 September 2021, and 16 September 2021.

Middle East respiratory syndrome coronavirus (MERS-CoV)

Latest update on 17 August 2021 (WHO website).

Up to 17 August 2021, a total of 5 cases of Middle East respiratory syndrome coronavirus, MERS-CoV, (three imported and 2 linked cases) have been confirmed in the UK through the on-going surveillance since September 2012.

On 2 February 2021, the National IHR Focal Point of the United Arab Emirates (UAE) notified WHO of one laboratory-confirmed case of MERS-CoV (WHO website).

Between 12 March and 31 July 2021, the National IHR Focal Point of Saudi Arabia reported four additional cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection, including one associated death. (WHO website).

From 2012 through 31 July 2021, a total of 2,578 laboratory-confirmed cases of MERS-CoV and 888 associated deaths were reported globally to WHO under the International Health Regulations (IHR 2005).

Further information on management and guidance of possible cases is available online. The latest ECDC MERS-CoV risk assessment can be found here, where it is highlighted that risk of widespread transmission of MERS-CoV remains very low.
Related links

Previous national COVID-19 reports
Previous weekly influenza reports
Annual influenza reports
COVID-19 vaccine surveillance reports
Previous COVID-19 vaccine surveillance reports
PHE monitoring of the effectiveness of COVID-19 vaccination
Investigation of SARS-CoV-2 variants of concern: technical briefings

UKHSA has delegated authority, on behalf of the Secretary of State, to process Patient Confidential Data under Regulation 3 The Health Service (Control of Patient Information) Regulations 2002

Regulation 3 makes provision for the processing of patient information for the recognition, control and prevention of communicable disease and other risks to public health.
About the UK Health Security Agency

The UK Health Security Agency is an executive agency, sponsored by the Department of Health and Social Care.

www.UKHSA.gov.uk

© Crown copyright 2021

Prepared by: The Immunisation and Countermeasures Division
For queries relating to this document, please contact: respсидsc@phe.gov.uk

Published: 14 October 2021

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.